Literature DB >> 23449607

Effects of low-dose atorvastatin on arterial stiffness and central aortic pressure augmentation in patients with hypertension and hypercholesterolemia.

Aggeliki I Kanaki1, Pantelis A Sarafidis, Panagiotis I Georgianos, Konstantinos Kanavos, Ioannis M Tziolas, Pantelis E Zebekakis, Anastasios N Lasaridis.   

Abstract

BACKGROUND: Experimental and clinical data suggest that statins exert anti-inflammatory and antiproliferative actions on vasculature beyond their lipid-lowering properties. Whether these pleiotropic effects of statins translate into a beneficial effect on arterial stiffness is not clear. This study aimed to evaluate the potential effects of low-dose atorvastatin treatment on arterial stiffness and central arterial pressure waveforms in patients with mild hypertension and hypercholesterolemia.
METHODS: In a double-blind, randomized, placebo-controlled fashion, 50 hypertensive and hypercholesterolemic patients were allocated to receive 10 mg of atorvastatin or placebo for 26 weeks. Arterial stiffness was assessed by aortic pulse-wave velocity (PWV) using a Sphygmocor device. Central arterial pressure waveform parameters were estimated by radial artery applanation tonometry. Heart rate-adjusted augmentation index (AIx(75)) was used as measure of wave reflections.
RESULTS: At study end, aortic PWV (9.0 ± 1.5 vs. 10.9 ± 2.6 m/sec; P < 0.001) and AIx(75) (24.9% ± 9.7% vs 28.8% ± 11.8%; P < 0.001) were significantly lower in the atorvastatin group than that placebo group. Furthermore, decreases in central aortic systolic blood pressure and pulse pressure were evident at study-end with atorvastatin but not with placebo (130 ± 8 vs. 138 ± 6 mm Hg, P < 0.001; 48 ± 7 vs. 53 ± 6 mm Hg, P < 0.05, respectively). Atorvastatin-induced reductions in aortic PWV during follow-up showed significant associations with changes in AIx(75) and central aortic systolic blood pressure and pulse pressure.
CONCLUSIONS: This study shows that low-dose atorvastatin treatment improves arterial stiffness and exerts a reduction on central aortic pressures. These effects may represent a potential mechanism of cardiovascular risk reduction observed with statin use. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov Database Identifier Number: NCT01126684.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23449607     DOI: 10.1093/ajh/hps098

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  34 in total

Review 1.  Strategies for Achieving Healthy Vascular Aging.

Authors:  Kristen L Nowak; Matthew J Rossman; Michel Chonchol; Douglas R Seals
Journal:  Hypertension       Date:  2018-01-08       Impact factor: 10.190

2.  Impact of Statin Therapy on the Blood Pressure-Lowering Efficacy of a Single-Pill Perindopril/Amlodipine Combination in Hypertensive Patients with Hypercholesterolemia.

Authors:  Yuriy Sirenko; Ganna Radchenko
Journal:  High Blood Press Cardiovasc Prev       Date:  2017-02-02

3.  Aortic perivascular adipose-derived interleukin-6 contributes to arterial stiffness in low-density lipoprotein receptor deficient mice.

Authors:  Bing Du; An Ouyang; Jason S Eng; Bradley S Fleenor
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-04-03       Impact factor: 4.733

4.  Association of arterial stiffness with cognition in patients with Lewy body disorder.

Authors:  Dong-Woo Ryu; Joong-Seok Kim; Jee-Eun Lee; Jeong-Wook Park; Yoon-Sang Oh; Jae-Young An; Kwang-Soo Lee
Journal:  Neurol Sci       Date:  2017-05-05       Impact factor: 3.307

Review 5.  The Role of Central Blood Pressure Monitoring in the Management of Hypertension.

Authors:  Adrian Ochoa; Gabriel Patarroyo-Aponte; Mahboob Rahman
Journal:  Curr Cardiol Rep       Date:  2018-04-19       Impact factor: 2.931

Review 6.  Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update.

Authors:  Vasilios G Athyros; Konstantinos Tziomalos; Niki Katsiki; Michael Doumas; Asterios Karagiannis; Dimitri P Mikhailidis
Journal:  World J Gastroenterol       Date:  2015-06-14       Impact factor: 5.742

Review 7.  Do Advanced Glycation End Products and Its Receptor Play a Role in Pathophysiology of Hypertension?

Authors:  Kailash Prasad; Manish Mishra
Journal:  Int J Angiol       Date:  2017-02-03

Review 8.  Druggable targets in the Rho pathway and their promise for therapeutic control of blood pressure.

Authors:  Rachel A Dee; Kevin D Mangum; Xue Bai; Christopher P Mack; Joan M Taylor
Journal:  Pharmacol Ther       Date:  2018-09-04       Impact factor: 12.310

9.  Relationship between cardio-ankle vascular index and plasma lipids in hypertension subjects.

Authors:  H Wang; J Liu; H Zhao; X Zhao; L Li; H Shi; S Zhan; J Liu
Journal:  J Hum Hypertens       Date:  2014-05-15       Impact factor: 3.012

10.  Lysyl Oxidase Induces Vascular Oxidative Stress and Contributes to Arterial Stiffness and Abnormal Elastin Structure in Hypertension: Role of p38MAPK.

Authors:  Sonia Martínez-Revelles; Ana B García-Redondo; María S Avendaño; Saray Varona; Teresa Palao; Mar Orriols; Fernanda R Roque; Ana Fortuño; Rhian M Touyz; Jose Martínez-González; Mercedes Salaices; Cristina Rodríguez; Ana M Briones
Journal:  Antioxid Redox Signal       Date:  2017-01-30       Impact factor: 8.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.